减剂量与全剂量直接口服抗凝药用于癌症患者延长期静脉血栓栓塞二级预防:随机试验的系统评价与荟萃分析
该系统评价与荟萃分析纳入3项随机对照试验共2178例活动性癌症且已完成至少6个月抗凝的静脉血栓栓塞患者,比较减剂量与全剂量直接口服抗凝药。复发性静脉血栓栓塞无显著差异(RR 0.87,95%CI 0.10-7.83,I²=0%),复合出血风险减剂量组数值上更低(RR 0.77,95%CI 0.55-1.06,p=0.07,I²=0%)。仅癌症试验亚组中减剂量阿哌沙班显著降低临床相关出血风险(RR 0.77,95%CI 0.60-0.99,p=0.05)且不增加静脉血栓栓塞复发。
要点
- 减剂量与全剂量阿哌沙班或利伐沙班的复发性静脉血栓栓塞风险无显著差异(RR 0.87,95%CI 0.10-7.83)。
- 复合出血风险减剂量组数值上更低但未达统计学显著(RR 0.77,95%CI 0.55-1.06,p=0.07)。
- 仅癌症试验亚组中减剂量阿哌沙班显著降低临床相关出血风险(RR 0.77,95%CI 0.60-0.99,p=0.05)。
核心结论
- 减剂量阿哌沙班或利伐沙班在癌症患者延长期静脉血栓栓塞二级预防中疗效与全剂量相当,并可能减少临床相关出血。
- 作者认为这些发现支持在部分活动性癌症患者中考虑剂量降级。
研究设计与样本
- 系统评价与荟萃分析,检索Embase和MEDLINE自建库至2025年4月1日。
- 纳入比较减剂量与全剂量直接口服抗凝药的随机对照试验,对象为活动性癌症且既往静脉血栓栓塞、已完成至少6个月治疗性抗凝的成人患者。
- 共纳入3项随机对照试验、2178例患者。
- 主要结局为复发性静脉血栓栓塞和主要出血与临床相关非主要出血的复合终点。
- 采用随机效应模型计算汇总风险比(RR)。
主要发现
- 减剂量与全剂量阿哌沙班或利伐沙班的复发性静脉血栓栓塞无显著差异(RR 0.87,95%CI 0.10-7.83,I²=0%)。
- 复合出血风险减剂量组数值上低于全剂量组(RR 0.77,95%CI 0.55-1.06,p=0.07,I²=0%),未达统计学显著。
- 仅癌症试验亚组(API-CAT和EVE,n=2126)中,减剂量阿哌沙班较全剂量显著降低临床相关出血风险(RR 0.77,95%CI 0.60-0.99,p=0.05),且不增加静脉血栓栓塞复发。
关键数值与推荐
- 复发性静脉血栓栓塞:减剂量 vs 全剂量直接口服抗凝药 RR 0.87(95%CI 0.10-7.83,I²=0%)。
- 复合出血终点:减剂量 vs 全剂量直接口服抗凝药 RR 0.77(95%CI 0.55-1.06,p=0.07,I²=0%)。
- 仅癌症试验亚组(API-CAT和EVE,n=2126)临床相关出血:减剂量阿哌沙班 vs 全剂量 RR 0.77(95%CI 0.60-0.99,p=0.05)。
临床怎么用
- 作者认为减剂量阿哌沙班或利伐沙班可为活动性癌症患者延长期静脉血栓栓塞二级预防提供与全剂量相当的疗效,并可能减少临床相关出血。
- 作者认为这些发现支持在部分活动性癌症患者中考虑剂量降级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with cancer are at high risk for both recurrent venous thromboembolism (VTE) and anticoagulant-associated bleeding. Direct oral anticoagulants (DOACs) have become a standard option for long-term VTE management; however, the safety and efficacy of reduced-dose regimens in cancer populations remain uncertain. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing reduced-dose versus full-dose DOACs in adult patients with active cancer and prior VTE who had completed at least 6 months of therapeutic anticoagulation. Embase and MEDLINE were searched from inception through April 1, 2025. Primary outcomes were recurrent VTE and a composite of major bleeding and clinically relevant non-major bleeding. Pooled risk ratios (RRs) were calculated using a random-effects model. Three RCTs including 2178 patients were eligible. There was no significant difference in recurrent VTE between reduced-dose and full-dose apixaban or rivaroxaban (RR, 0.87; 95% CI, 0.10-7.83; I2 = 0%). The composite bleeding risk was numerically lower with reduced-dose DOACs (RR, 0.77; 95% CI, 0.55-1.06; p = 0.07; I2 = 0%). In a subgroup analysis of cancer-only trials (API-CAT and EVE; n = 2126), reduced-dose apixaban significantly reduced the risk of clinically relevant bleeding (RR, 0.77; 95% CI, 0.60-0.99; p = 0.05) without increasing VTE recurrence. Reduced-dose apixaban or rivaroxaban offers comparable efficacy to full-dose regimens for extended secondary VTE prophylaxis in cancer patients, with a potential reduction in clinically relevant bleeding. These findings support consideration of dose de-escalation in select patients with active cancer.
引用
- Mahmoud A, Eltaher B, Shah P, et al. Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants for Extended Secondary Venous Thromboembolism Prophylaxis in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Trials. Am J Hematol. 2025. PMID: 40990099. doi:10.1002/ajh.70090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。